Streetbeat News

SHIEF

Shield Therapeutics plc

https://www.shieldtherapeutics.com/

CEO

Carl Andrew Sterritt

Industry

Medicinal and Botanical Manufacturing

Open

0.02

Mkt cap

28M

Volume

High

0.04

P/E Ratio

-0.71

52-wk high

0.08

Low

0.02

Div yield

N/A

52-wk low

0.01

Shield Therapeutics shares increased after announcing a $10 million fundraising from AOP Health International, which will purchase new shares at a price slightly above the previous day's closing.

Portfolio Pulse from

December 06, 2024 | 5:00 pm

Shield Therapeutics PLC is conducting a $10 million fundraiser with backing from its largest investor, AOP Health International. The new shares are priced at a slight premium to the previous closing price.

Portfolio Pulse from

December 06, 2024 | 1:00 pm

Shield Therapeutics' shares rose 27% following a trading update revealing strong sales of its iron deficiency drug ACCRUFeR, with an increased net selling price. The company is on track to meet its 2024 revenue target, crucial for its debt agreement with SWK Funding.

Portfolio Pulse from

November 21, 2024 | 9:45 am

Shield Therapeutics reports strong sales of its iron deficiency drug ACCRUFeR, with a price increase boosting revenues. The company is on track to meet its 2024 revenue target of $31.5 million, as required by its debt agreement with SWK Funding.

Portfolio Pulse from

November 21, 2024 | 8:00 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.